Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake ...

After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering ...

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering and weight-lowering therapies declined, an analysis showed. The ...

As the Food and Drug Administration cracks down on compounded versions of popular weight loss drugs Wegovy (semaglutide) and Zepbound (tirzepatide), Americans who rely on these cheaper medications ...

and falsely claiming to sell ‘personalised’ compounded tirzepatide.” Mochi Health, which also develops a compounded version of Novo Nordisk’s GLP-1RA semaglutide, did not immediately ...